Plain-English translation of NCT06940739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first human studies of , a new medication that combines an immune-boosting protein with an antibody to help fight melanoma. The trial will test whether works safely and effectively when given either before or after a cell therapy treatment called lifileucel. Researchers hope this medication will help your immune system attack melanoma cells more effectively.
Many patients with advanced melanoma stop responding to standard immune checkpoint inhibitor treatments, leaving them with limited options. This trial exists to see if this new medication can help patients whose melanoma has continued to grow despite prior treatments.
You likely qualify if…
You likely don't qualify if…
This is an early-stage study, so the research team will carefully monitor your health and watch for side effects. Depending on which part of the trial you join, you may receive the new medication either before or after the lifileucel cell therapy treatment. You will have regular visits with the study team for blood tests, scans, and checkups to see how well the treatment is working and to track any side effects. The exact schedule and duration of visits will depend on how your body responds to the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Australia